Vor Biopharma (NYSE:VOR – Get Free Report) is one of 8,069 publicly-traded companies in the “” industry, but how does it compare to its rivals? We will compare Vor Biopharma to related businesses based on the strength of its institutional ownership, valuation, dividends, profitability, earnings, risk and analyst recommendations.
Insider and Institutional Ownership
90.0% of Vor Biopharma shares are owned by institutional investors. Comparatively, 54.0% of shares of all “” companies are owned by institutional investors. 12.4% of Vor Biopharma shares are owned by insiders. Comparatively, 14.7% of shares of all “” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Vor Biopharma has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500. Comparatively, Vor Biopharma’s rivals have a beta of 0.58, suggesting that their average share price is 42% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vor Biopharma | 0 | 0 | 8 | 0 | 3.00 |
| Vor Biopharma Competitors | 4388 | 24199 | 30535 | 621 | 2.46 |
Vor Biopharma currently has a consensus target price of $15.19, suggesting a potential upside of 551.82%. As a group, “” companies have a potential upside of 371.83%. Given Vor Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Vor Biopharma is more favorable than its rivals.
Profitability
This table compares Vor Biopharma and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vor Biopharma | N/A | N/A | N/A |
| Vor Biopharma Competitors | -1,355.70% | -288.63% | -24.49% |
Earnings and Valuation
This table compares Vor Biopharma and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Vor Biopharma | N/A | N/A | -1.14 |
| Vor Biopharma Competitors | $6.32 billion | $467.29 million | -121.44 |
Vor Biopharma’s rivals have higher revenue and earnings than Vor Biopharma. Vor Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Vor Biopharma beats its rivals on 8 of the 12 factors compared.
Vor Biopharma Company Profile
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
